Animal models. Male Wistar rats weighing 200–250 g were obtained from the Animal Center of National Cheng Kung University Medical College. STZ-induced diabetic rats, used as a type 1 diabetes model, were prepared by administering an intravenous injection of STZ (Sigma Chemical, St. Louis, MO) (60 mg/kg) to male Wistar rats aged 8–10 weeks after the animals were fasted for 3 days, . Rats with plasma glucose concentrations ≥20 mmol/l in addition to polyuria and other diabetic features were considered to have type 1 diabetes. All studies were carried out 2 weeks after the injection of STZ. All animal procedures were performed according to the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health as well as the guidelines of the Animal Welfare Act. Experimental protocols. Experiment 1: hydrocodone muscle relaxer, Effect of tramadol on plasma glucose. The rats were divided into two groups for the investigation. After fasting overnight, STZ-induced diabetic rats in group 1 received an intravenous injection of tramadol (Pairon Pharmaceuticals, Kaohsiung City, Taiwan) at the desired doses, and blood samples (0.1 ml) were collected under sodium pentobarbital anesthesia (30 mg/kg i.p.) from the tail vein for measurement of plasma glucose. In the preliminary experiments, tramadol was found to produce the maximal plasma glucose–lowering effect in STZ-induced diabetic rats 30 min after injection. Thus, the effects of tramadol on plasma glucose, insulin, and C-peptide were determined using blood samples collected at 30 min after the injection. STZ-induced diabetic rats receiving a similar injection of vehicle at the same volume were used as controls and defined as group 2, hydrocodone muscle relaxer. Further experiments were performed with pharmacological inhibitors, either naloxone or naloxonazine, hydrocodone muscle relaxer, which were obtained from Research Biochemical (Natick, hialeah, MA). These inhibitors were intravenously injected into fasted rats 30 min before the injection of tramadol. Experiment 2: Investigation for the role of 5-hydroxytrptamine in the action of tramadol. STZ-induced diabetic rats received an intravenous injection of p-chlorophenylalanine (PCPA) at 300 mg/kg once daily for 3 successive days, hydrocodone muscle relaxer. The control group received the same volume of vehicle in the schedule. Changes of 5-hydroxytrptamine (5-HT) were followed by the levels of 5-HT and 5-hydroxyindole acetic acid (5-HIAA) in plasma obtained from STZ-induced diabetic rats receiving PCPA or vehicle. Determination of 5-HT or 5-HIAA was performed by electrochemical detection as previously reported (14). Then, hydrocodone muscle relaxer, plasma glucose–lowering activity of tramadol (50 μg/kg) in STZ-induced diabetic rats receiving PCPA was compared with that in vehicle-treated STZ-induced diabetic rats. Also, STZ-induced diabetic rats receiving oral administration of fluoxetine (Eli Lilly) at 20 mg/kg were used to estimate the alteration in plasma glucose (15). Experiment 3: Effects of tramadol on glucose utilization. The effects of tramadol on glucose uptake were studied using the uptake of radioactive glucose analog, 2-[1-14C]deoxy-d-glucose (2-DG), in isolated soleus muscle of STZ-induced diabetic rats. Hepatocytes isolated from another group of STZ-induced diabetic rats were also used to determine the effect of tramadol on [14C]glucose incorporation into glycogen. Experiment 4: Effect of tramadol on gene expression. STZ-induced diabetic rats were given injections of vehicle, tramadol (50 μg/kg), naloxone (10 μg/kg), hydrocodone muscle relaxer, or both naloxone and tramadol every 8 h, three times daily, into the tail vein. In the preliminary experiments, tramadol was found to significantly modify the mRNA and protein levels for GLUT4 and PEPCK in STZ-induced diabetic rats after 4 days of treatment, . Thus, the effects of tramadol on gene expression of GLUT4 and PEPCK were determined using samples collected after 4 days of treatment. Normal rats received a similar treatment of vehicle and were used as controls, hydrocodone muscle relaxer. After the final treatment, animals were killed without fasting. Liver and soleus muscle were immediately removed, frozen in liquid nitrogen, hydrocodone muscle relaxer, and stored at −70°C for Northern and Western blot analysis. Blood samples were also collected from the femoral vein of these rats before they were killed, hydrocodone muscle relaxer. Laboratory determinations. Blood samples (0.1 ml) were collected by a chilled syringe containing 10 IU heparin from the tail vein of the rats while they were under anesthesia with sodium pentobarbital (30 mg/kg i.p.). Concentration of plasma glucose was measured by the glucose oxidase method via an analyzer (Quik-Lab; Ames/Miles, Elkhart, IN) (16). Radioimmunoassay (RIA) was performed to measure plasma insulin or C-peptide using a commercial kit from Linco (St. Charles, MO), . A plasma sample from an STZ-induced diabetic rat was added with standard insulin or C-peptide to raise the level into the detectable range of RIA. The given value was obtained by subtracting the added standard from the measured value, . Measurement of glucose uptake into soleus muscle. Soleus muscle was isolated from STZ-induced diabetic rats and divided into long longitudinal strips (35–25 mg per strip) as previously described (17). After a 30-min preincubation period, hydrocodone muscle relaxer, the muscle tissue was transferred to fresh incubation flasks with or without the presence of antagonist (either naloxone or naloxonazine) at appropriate concentrations for 30 min at 37°C and then incubated with tramadol at the desired concentrations at 37°C for another 30 min under continuous shaking at 40 cycles/min, . The muscle tissue was subsequently incubated with 50 μl Krebs-Ringer bicarbonate buffer (KRBB) containing 2-DG (1 μCi/ml) (NEN Research, hydrocodone muscle relaxer, Boston, other drug interactions with phentermine, MA) for 5 min at 37°C. Reactions were terminated by quickly blotting the muscles and dissolving them in 0.5 ml of 0.5 N NaOH for 45 min before neutralization with 0.5 ml of 0.5 N HCl. After centrifugation, 800 μl of each supernatant was mixed with 1 ml aqueous counting scintillant (ASC; generic tramadol er; Amersham, Arlington Heights, hialeah, IL) and the radioactivity was determined using a β-counter (Beckman LS6000, Beckman, Fullerton, CA) (17). Uptake of 2-DG, assessed after preincubation of the muscle with 20 μmol/l cytochalasin B (Sigma Chemical), was subtracted from the total muscle–associated radioactivity (18). Specific 2-DG uptake was expressed as the percentage of basal uptake that was obtained from soleus muscle incubated with KRBB only. Measurement of glycogen synthesis in hepatocytes. Hepatocytes were prepared as previously described (19). After the 30-min preincubation period in KRBB at 37°C, hydrocodone muscle relaxer, 2 × 106 hepatocytes were transferred to fresh incubation flasks containing [U-14C]glucose (0.25 μCi/ml) (NEN Research), with or without the presence of antagonist, at appropriate concentrations for 30 min at 37°C and then incubated with tramadol at the desired concentrations at 37°C for 1 h, other drug interactions with phentermine, which was the optimal time obtained from preliminary experiments under continuous shaking. The incorporation of [U-14C]glucose into glycogen was determined by ethanol precipitation (20). Label incorporation into glycogen was expressed as the percentage of basal level that was obtained from hepatocytes incubated with KRBB only, hydrocodone muscle relaxer. Northern blotting analysis, . Total RNA was extracted from liver or soleus muscle of experimental animals using the Ultraspec-II RNA extraction system (Bioteck, Houston, TX). For Northern blotting analysis, RNA (20 μg) was denatured by heating at 55°C for 15 min in a solution containing 2.2 mmol/l formaldehyde and 50% formamide (vol/vol). Aliquots of total RNA were then size-fractionated in a 1.2% agarose/formaldehyde gel, . Ethidium bromide staining was used to identify the position of the 18S and 28S rRNA subunits and to confirm that equivalent amounts of undegraded RNA had been loaded. The RNA was transferred to a Hybond-N membrane (Amersham, are oxycodone and hydrocodone the same, Bucks, U.K.). GLUT4 and PEPCK mRNA levels were detected using random prime-labeled full-length cDNA under stringent hybridization conditions. Intensity of the mRNA bands on the blot was quantified by scanning densitometry (Hoefer, San Francisco, CA). The response of β-actin was used as an internal standard. Western blot analysis. After homogenization of liver and skeletal muscle using a glass/Teflon homogenizer, the homogenates (50 μg) were separated by SDS-PAGE, and Western blot analysis was performed as previously described (17) using either anti-rat antibody to bind GLUT4 (1:1,000) (Genzyme Diagnostics, Cambridge, generic tramadol er, MA) in skeletal muscle or another anti-rat antibody (1:1,000) to bind PEPCK in liver. Blots were incubated with the appropriate peroxidase-conjugated secondary antibodies. After removal of the secondary antibody, blots were washed as described above and developed by autoradiography using the ELC-Western blotting system (Amersham, Braunschweig, Germany). Densities of the obtained immunoblots were quantified using a laser densitometer, with GLUT4 at 45 KDa and PEPCK at 69.5 KDa. Statistical analysis. The plasma glucose–lowering activity was determined in rats that received tramadol injection under anesthesia. Data are expressed as the means ± SE for the number (n) of animals in each group, as indicated in the tables and figures. Repeated measures of analysis of variance were used to analyze the changes in plasma glucose and other parameters. Where appropriate, the Dunnett range post hoc comparisons were used to determine the source of significant differences. The concentration for 50% effect (ED50) was obtained from nonlinear regression analysis. P < was considered statistically significant.
Do not take high dosage for longer period of time if your do not recommend you to do so. Do not take tramadol without consulting your doctor. Follow the prescription before taking this medicine. You can find the directions on your prescription label, hydrocodone muscle relaxer. Try not to take more than 300 mg dosages per day, . Take this medicine with water, hydrocodone muscle relaxer. You can take it before or after taking food. Tramadol is recommended for oral use, so do not crush it. Do not inhale the crushed tablet or diluted the powder with any liquid, hydrocodone muscle relaxer. Also never try to inject it otherwise it can cause some serious life threatening effects. Also never chew it. Try to check the expiring date before buying the medicine. Do not buy or take extended release or delayed release tablets, hydrocodone muscle relaxer. All this can cause life threatening problems. Remember that this tablet shell may pass into your stools. This problem is very normal with all the tramadol users, . If tramadol is not working then ask your doctor to change the medicine. Do not change the medicine without consulting tour doctor. Also do not stop using tramadol if you suffer from some minor side effects like sweating, diarrhea, are oxycodone and hydrocodone the same, nauseam chills, anxiety, breathing problem etc, hydrocodone muscle relaxer. In that case consult with your doctor about the side effects and follow his instruction to avoid the side effects. Where to store tramadol? Tramadol is recommended to store at room temperature. Keep it away from moisture and heat, . It is a drug of abuse so be aware of it. Keep it away from children, . Do not use this medicine without proper prescription. What will you do if you miss a dose? If you miss a dose then take the missed dose as soon as you remember. Skip the missed dose if it is time for your next dose. Never try to take extra doses to make up the missed dosage. Also do not take any extra medicine without consulting doctor, hydrocodone muscle relaxer. What to do if you overdose? Tramadol overdose can be fatal. Consult your physician as soon as possible if you overdose, hydrocodone muscle relaxer. Drowsiness, shallow breathing, slow heartbeat, extreme weakness, cold or clammy skin, are oxycodone and hydrocodone the same, feeling light-headed, fainting, or coma etc are some symptoms of overdose, hydrocodone muscle relaxer. What should you avoid while taking tramadol? While taking tramadol do not drink alcohol. It can cause some harmful effect on your body, hydrocodone muscle relaxer. It can decrease your breathing if alcohol is used together with tramadol. Some other medicines like allergy medicine, depression or anxiety, sleeping pills, narcotic pain medicine, and medicine for seizures, can add to sleepiness caused by tramadol. If you are using these medicines with tramadol then tell your doctor about it, hydrocodone muscle relaxer. Tramadol has some side effects so try to know about all the side effects before taking this medicine. Do not take tramadol while driving as it requires you to be awake and alert.
|
